ALTERITY THERAPEUTICS Business Summary

Alterity Therapeutics Ltd (ATHE) is a clinical-stage biotechnology company specializing in the development of disease-modifying therapies for neurodegenerative disorders, with a primary focus on Parkinsonian conditions such as Multiple System Atrophy (MSA). The company’s business model is centered on the research and clinical advancement of its lead candidate, ATH434, a small molecule designed to inhibit protein aggregation and restore iron balance in the brain. Alterity generates revenue primarily through research and development tax incentives and strategic grants, while pursuing a long-term commercialization strategy based on licensing agreements and non-dilutive funding partnerships with global pharmaceutical firms. The company operates as a single-segment entity focused on its proprietary chemical library and drug discovery platform, targeting a projected $2.4 billion market for MSA. In the competitive landscape, Alterity contends with larger players like Denali Therapeutics and Amylyx Pharmaceuticals, as well as niche peers such as Inhibikase Therapeutics and Annexon; it distinguishes itself as a high-potential, small-cap innovator holding both FDA Fast Track and Orphan Drug designations for its specialized orphan-disease pipeline. Originally founded as Prana Biotechnology by Geoffrey Kempler, the company is currently led by Dr. David Stamler, who serves as Managing Director and Chief Executive Officer. Dr. Stamler brings extensive pedigree in clinical development, having previously served as Chief Medical Officer at Auspex Pharmaceuticals and Vice President of Clinical Development at Teva Pharmaceutical Industries. The leadership team is further bolstered by Julian Babarczy, an experienced investment professional with over two decades in funds management, who was appointed Chairman of the Board in late 2025. Scientific strategy is guided by Chief Scientific Advisor Dr. Rudolph Tanzi, a renowned Harvard Medical School professor and pioneer in Alzheimer’s research, alongside CFO Abby Macnish Niven. Alterity maintains a high-profile investor base, including the Michael J. Fox Foundation for Parkinson’s Research, and institutional backing from firms such as Point72 Asset Management and Citadel Advisors.